| 48.48 -0.09 (-0.19%) | 12-05 10:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 57.59 | 1-year : | 67.26 |
| Resists | First : | 49.31 | Second : | 57.59 |
| Pivot price | 47.57 |
|||
| Supports | First : | 47.14 | Second : | 45.81 |
| MAs | MA(5) : | 48.3 |
MA(20) : | 47.61 |
| MA(100) : | 42.33 |
MA(250) : | 0 | |
| MACD | MACD : | 0.8 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 82.1 |
D(3) : | 80.4 |
| RSI | RSI(14): 60.5 |
|||
| 52-week | High : | 49.31 | Low : | 31.71 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GSK ] has closed below upper band by 20.0%. Bollinger Bands are 12% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 49.1 - 49.38 | 49.38 - 49.64 |
| Low: | 47.88 - 48.19 | 48.19 - 48.47 |
| Close: | 48.13 - 48.62 | 48.62 - 49.07 |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
Thu, 04 Dec 2025
Key facts: GSK Buyback Reaches 237M Shares; CDC Talks Impact Vaccines - TradingView
Thu, 04 Dec 2025
CDC vaccine panel voting on hepatitis b shots postponed over confusion (GSK:NYSE) - Seeking Alpha
Thu, 04 Dec 2025
Analysts Offer Predictions for GSK's Q2 Earnings (NYSE:GSK) - MarketBeat
Wed, 03 Dec 2025
AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report - Benzinga
Wed, 03 Dec 2025
Here's Why GSK (GSK) is a Strong Growth Stock - Yahoo Finance
Wed, 03 Dec 2025
GSK (LON:GSK) Stock Price Passes Above 200-Day Moving Average - What's Next? - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,020 (M) |
| Shares Float | 3,900 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 19.1 (%) |
| Shares Short | 12,550 (K) |
| Shares Short P.Month | 13,330 (K) |
| EPS | 3.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.01 |
| Profit Margin | 17 % |
| Operating Margin | 32.6 % |
| Return on Assets (ttm) | 7.1 % |
| Return on Equity (ttm) | 41.5 % |
| Qtrly Rev. Growth | 6.6 % |
| Gross Profit (p.s.) | 11.53 |
| Sales Per Share | 15.92 |
| EBITDA (p.s.) | 4.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 7,790 (M) |
| Levered Free Cash Flow | 3,750 (M) |
| PE Ratio | 13.78 |
| PEG Ratio | 0 |
| Price to Book value | 12.09 |
| Price to Sales | 3.04 |
| Price to Cash Flow | 12.57 |
| Dividend | 0.41 |
| Forward Dividend | 0 |
| Dividend Yield | 0.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|